Celcuity Inc. (CELC): Price and Financial Metrics


Celcuity Inc. (CELC)

Today's Latest Price: $5.97 USD

0.21 (-3.40%)

Updated Aug 12 11:44am

Add CELC to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 58 in Medical - Diagnostics/Research

See all "A" rated Strong Buy stocks

CELC Daily Price Range
CELC 52-Week Price Range

CELC Stock Price Chart Technical Analysis Charts


CELC Price/Volume Stats

Current price $5.97 52-week high $20.86
Prev. close $6.18 52-week low $4.03
Day low $5.85 Volume 2,629
Day high $6.17 Avg. volume 21,227
50-day MA $6.84 Dividend yield N/A
200-day MA $8.64 Market Cap 61.34M

Celcuity Inc. (CELC) Company Bio


Celcuity LLC, a cellular analysis company, discovers cancer sub-types and commercializes diagnostic tests to enhance the response rates of cancer patients treated with targeted therapies in the United States. It develops CELx tests to diagnose breast, lung, colon, ovarian, kidney, bladder, and hematological cancers. The company was founded in 2012 and is based in Minneapolis, Minnesota.





CELC Latest News Stream


Event/Time News Detail
Loading, please wait...

CELC Latest Social Stream


Loading social stream, please wait...

View Full CELC Social Stream

Latest CELC News From Around the Web

Below are the latest news stories about Celcuity Inc that investors may wish to consider to help them evaluate CELC as an investment opportunity.

Celcuity Inc. Schedules Release of Second Quarter 2020 Financial Results and Conference Call

MINNEAPOLIS, MN / ACCESSWIRE / July 24, 2020 / Celcuity Inc.

Yahoo | July 24, 2020

Celcuity Hosting Call on CELsignia Pathway Activity Test for Ovarian Cancer

MINNEAPOLIS, MN / ACCESSWIRE / July 1, 2020 / Celcuity Inc. (CELC), a clinical-stage biotechnology company translating discoveries of new cancer sub-types into pioneering diagnostics and expanded therapeutic options for cancer patients, announced today that it will host a call to discuss its CELsignia pathway activity test for ovarian cancer on Monday, July 13, 2020 at 1:00 pm Eastern Time. The call will feature a presentation by Celcuity's management team including CEO and Co-Founder, Brian Sullivan and Chief Scientific Officer and Co-Founder, Lance Laing, Ph.D. They will provide a corporate overview and an update on their 3rd Generation diagnostic platform including recent data presented at AACR for their first CELsignia Pathway Activity Test for ovarian cancer. The studies presente...

Yahoo | July 1, 2020

Celcuity Presents Data at AACR Annual Meeting for CELsignia Pathway Activity Test for Ovarian Cancer

MINNEAPOLIS, MN / ACCESSWIRE / June 22, 2020 / Celcuity Inc. (CELC), a clinical stage biotechnology company translating discoveries of new cancer sub-types into pioneering diagnostics and expanded therapeutic options for cancer patients, announced today that the Company presented results from studies of its first CELsignia Pathway Activity Test for ovarian cancer in an e-poster at the American Association for Cancer Research (AACR) Annual Meeting. The 2020 AACR Virtual Annual Meeting is being held in place of the 2020 in-person Annual Meeting. The CELsignia test for ovarian cancer identifies a subset of ovarian cancer patient whose tumors have abnormal c-Met signaling coincident with abnormal HER2 signaling.

Yahoo | June 22, 2020

Celcuity Reports First Quarter 2020 Financial Results and Recent Business Highlights

Significant progress made in development of new, highly precise diagnostics using proprietary CELsignia platform Expect to announce new clinical trial collaborations with pharmaceutical companies and trial ...

Yahoo | May 7, 2020

Celcuity Inc. Schedules Release of First Quarter 2020 Financial Results and Conference Call

MINNEAPOLIS, MN / ACCESSWIRE / April 23, 2020 / Celcuity Inc. (CELC), a functional cellular analysis company that is developing companion diagnostic tests designed to expand the eligible patient populations for targeted therapies, announced that it will release its financial results for the first quarter 2020 after the stock market close on Thursday, May 7, 2020. Our proprietary CELsignia diagnostic platform is currently the only commercially ready technology that we are aware of that uses a patient's living tumor cells to identify the cellular activity that may be driving a patient's cancer.

Yahoo | April 23, 2020

Read More 'CELC' Stories Here

CELC Price Returns

1-mo 3.65%
3-mo 17.06%
6-mo -42.04%
1-year -69.98%
3-year N/A
5-year N/A
YTD -43.89%
2019 -55.65%
2018 26.60%
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8526 seconds.